GSK-J4 HCl is selective inhibitor of jumonji H3K27 demethylase. It can attenuate lipopolysaccharide (LPS)-induced proinflammatory cytokine production.

JIB-04 is a selective inhibitor of jumonji histone demethylase with IC50s of 230/340/855/445/435/1100, and 290 nM for JARID1A/JMJD2E/JMJD3/JMJD2A/JMJD2B/JMJD2C, and JMJD2D, respectively.

CPI-455 is a selective inhibitor of KDM5 demethylases and can reduce survival of drug-tolerant cancer cells.

GSK-J1 is a H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM for JMJD3 (KDM6B) and UTX (KDM6A), respectively.

IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.